Top

Neurological Sciences

Published in:

01-02-2021 | Parkinson's Disease | Original Article

Urinary kynurenine as a biomarker for Parkinson’s disease

Authors: Jia-he Bai, Ya-li Zheng, Yong-peng Yu

Published in: Neurological Sciences | Issue 2/2021

Abstract

Objective

To examine whether urine kynurenine (KYN) levels were associated with early-stage Parkinson’s disease (PD), as well as the value of urine KYN as a potential biomarker in early-stage PD.

Method

Eighty-two participants including 41 PD patients and 41 healthy controls were enrolled into this study. Urine KYN levels were measured with a KYN enzyme-linked immunoassay kit. In order to explore the correlation between some clinical parameters and urine KYN, the clinical parameters for these participants were recorded. Diagnostic value and clinical relevance of urine KYN were assessed by using receiver operator characteristic (ROC) curve and correlation analysis.

Results

Urine KYN levels were significantly higher in the PD group than in the healthy group (891.95 ± 276.65 pg/ml vs. 640.11 ± 122.37 pg/ml, p = 0.000). The correlations between urine KYN levels and clinical parameters are as follows: Hoehn-Yahr stage (r = 0.676, p = 0.000), disease duration (r = 0.772, p = 0.000), Mini-Mental State Examination scores (r = −0.434, p = 0.005). There was no statistically significant correlation between urine KYN with age, low-density cholesterol (LDL), triglycerides (TG), cholesterol (TC), homocysteine (HCY), uric acid (UA), and glomerular filtration rate (GFR). The ROC analysis showed that urine KYN optimal cutoff value of 751.88 pg/ml had a sensitivity of 65.9% and a specificity of 90.2% for distinguishing between PD and controls, with an area under the curve (AUC) of 0.776.

Conclusion

Urine KYN were significantly associated with PD severity and mild cognitive impairment. Urine KYN may be a new biomarker for early-stage PD.

Halbach OB, Schober A, Krieglstein K (2004) Genes, proteins, and neurotoxins involved in Parkinson’s disease. Prog Neurobiol 73(3):151–177. https://doi.org/10.1016/j.pneurobio.2004.05.002CrossRef

Yazar T, Yazar HO, Zayimoğlu E, Çankaya S (2018) Incidence of sarcopenia and dynapenia according to stage in patients with idiopathic Parkinson’s disease. Neurol Sci 39:1415–1421. https://doi.org/10.1007/s10072-018-3439-6CrossRefPubMed

Elbaz A, Carcaillon L, Kab S, Moisan F (2016) Epidemiology of Parkinson’s disease. Rev Neurol 172:14–26. https://doi.org/10.1017/S0317167100046321CrossRefPubMed

Xu XM, Dong MX, Feng X, Liu Y, Pan JX, Jia SY, Cao D, Wei YD (2018) Decreased serum proNGF concentration in patients with Parkinson’s disease. Neurol Sci 39:91–96. https://doi.org/10.1007/s10072-017-3157-5CrossRefPubMed

Dexter DT, Jenner P (2013) Parkinson disease: from pathology to molecular disease mechanisms. Free Radical Bio Med 62(5):132–144. https://doi.org/10.1016/j.freeradbiomed.2013.01.018CrossRef

Lopiano L, Modugno N, Marano P, Sensi M, Meco G, Cannas A, Gusmaroli G, Tamma F, Mancini F, Quatrale R, Costanzo AM, Gualberti G, Melzi G, di Luzio Paparatti U, Antonini A (2016) Motor outcomes in patients with advanced Parkinson’s disease treated with levodopa/carbidopa intestinal gel in Italy: an interim analysis from the GREENFIELD observational study. Neurol Sci 37:1785–1792. https://doi.org/10.1007/s10072-016-2664-0CrossRefPubMedPubMedCentral

Debapriya, Garabadu, Nidhi (2019) Mitochondrial metabolism: a common link between neuroinflammation and neurodegeneration. Behav Pharmacol 30(8):642–652

Zhong RX, Qin YJ, Chen ZY, Zhang JT, Zhao SZ et al (2019) Progress in pathogenesis and early diagnosis of Parkinson’s disease. Clin Med 35(3):276–280. https://doi.org/10.3760/cma.j.issn.1008-6315.2019.03.019CrossRef

Kalia LV, Lang AE (2015) Parkinson’s disease. Lancet 386:896–912. https://doi.org/10.1016/S0140-6736(14)61393-3CrossRefPubMed

10.

Tan L, Yu JT, Tan L (2012) The kynurenine pathway in neurodegenerative diseases: mechanistic and therapeutic considerations. J Neurol Sci 323:1–2. https://doi.org/10.1016/j.jns.2012.08.005CrossRefPubMed

11.

Widner B, Leblhuber F, Fuchs D (2002) Increased neopterin production and tryptophan degradation in advanced Parkinson’s disease. J Neural Transm 109(2):181–189. https://doi.org/10.1007/s007020200014CrossRefPubMed

12.

Tang YM, Zhang FF, Liu Y, Chang DD, Ren YP (2011) Significance of kynurenine, kynurenic acid and tryptophan in patients with Parkinson’s disease. Guangdong Med J 32(13):1678–1681. https://doi.org/10.3969/j.issn.1001-9448.2011.13.013CrossRef

13.

Schwarcz R, Stone TW (2016) The kynurenine pathway and the brain: challenges, controversies and promises. Neuropharmacology 112:234–247. https://doi.org/10.1016/j.neuropharm.2016.08.003CrossRef

14.

Maximilian TA, Lilly S, Robert S, Michel G, Sophie E et al (2018) Importance of kynurenine 3-monooxygenase for spontaneous firing and pharmacological responses of midbrain dopamine neurons: relevance for schizophrenia. Neuropharmacology 138:130–139. https://doi.org/10.1016/j.neuropharm.2018.06.003CrossRef

15.

Rossi F, Miggiano R, Ferraris D, Rizzi M (2019) The synthesis of kynurenic acid in mammals: an updated kynurenine aminotransferase structural KATalogue. Front Mol Biosci 6:7. https://doi.org/10.3389/fmolb.2019.00007CrossRefPubMedPubMedCentral

16.

Albuquerque EX, Schwarcz R (2013) Kynurenic acid as an antagonist of α7 nicotinic acetylcholine receptors in the brain: facts and challenges. Biochem Pharmacol 85(8):1027–1032. https://doi.org/10.1016/j.bcp.2012.12.014CrossRefPubMed

17.

Linderholm KR, Alm MT, Larsson MK, Olsson SK, Goiny M, Hajos M, Erhardt S, Engberg G (2015) Inhibition of kynurenine aminotransferase II reduces activity of midbrain dopamine neurons. Neuropharmacology 102:42–47. https://doi.org/10.1016/j.neuropharm.2015.10.028CrossRefPubMed

18.

Ramos-Chávez LA, Lugo HR, González ED, Pineda B, Ríos C et al (2018) Relevance of alternative routes of kynurenic acid production in the brain. Oxidative Med Cell Longev 2018:1–14. https://doi.org/10.1155/2018/5272741CrossRef

19.

Katalin S, Szabó E, Vécsei L (2018) Mitochondria, oxidative stress and the kynurenine system, with a focus on ageing and neuroprotection. Molecules 23(1):191. https://doi.org/10.3390/molecules23010191CrossRef

20.

Guillemin GJ (2012) Quinolinic acid, the inescapable neurotoxin. FEBS J 279(8):1356–1365. https://doi.org/10.1111/j.1742-4658.2012.08485.xCrossRefPubMed

21.

Gulaj E, Pawlak K, Bien B, Pawlak D (2010) Kynurenine and its metabolites in Alzheimer’s disease patients. Advances in Medical Sciences 55(2):204–211. https://doi.org/10.2478/v10039-010-0023-6CrossRefPubMed

22.

Capuron L, Miller AH (2011) Immune system to brain signaling: neuropsychopharmacological implications. Pharmacol Ther 130:226–238. https://doi.org/10.1016/j.pharmthera.2011.01.014CrossRefPubMedPubMedCentral

23.

Hartai Z, Klivenyi P, Janaky T, Penke B, Dux L, Vecsei L (2005) Kynurenine metabolism in plasma and in red blood cells in Parkinson’s disease. J Neurol Sci 239(1):31–35. https://doi.org/10.1016/j.jns.2005.07.006CrossRefPubMed

24.

Zadori D, Klivényi P, Plangár I, Toldi J, Vécsei L (2011) Endogenous neuroprotection in chronic neurodegenerative disorders: with particular regard to the kynurenines. Cell Mol Med 15:701–717. https://doi.org/10.1111/j.1582-4934.2010.01237.xCrossRef

25.

Lim CK, Fernández-Gomez FJ, Braidy N, Estrada C, Costa C, Costa S, Bessede A, Fernandez-Villalba E, Zinger A, Herrero MT, Guillemin GJ (2016) Involvement of the kynurenine pathway in the pathogenesis of Parkinson’s disease. Prog Neurobiol 155:76–95. https://doi.org/10.1016/j.pneurobio.2015.12.009CrossRefPubMed

26.

Chess AC, Simoni MK, Alling TE, Bucci DJ (2007) Elevations of endogenous kynurenic acid produce spatial working memory deficits. Schizophren Bull 33:797–804. https://doi.org/10.1093/schbul/sbl033CrossRef

27.

Young S, Koo H, Kim et al (2018) Indoleamine 2,3-dioxygenase-dependent neurotoxic kynurenine metabolism contributes to poststroke depression induced in mice by ischemic stroke along with spatial restraint stress. Oxidative Medicine & Cellular Longevity 2018:241384–241315. https://doi.org/10.1155/2018/2413841CrossRef

28.

Ilzecka J, Kocki T, Stelmasiak Z, Turski WA (2003) Endogenous protectant kynurenic acid in amyotrophic lateral sclerosis. Acta Neurol Scand 107:412–418. https://doi.org/10.1034/j.1600-0404.2003.00076.xCrossRefPubMed

29.

Beal MF, Matson WR, Storey E, Milbury P, Ryan EA et al (1992) Kynurenic acid concentrations are reduced in Huntington’s disease cerebral cortex. J Neurol Sci 108(1992):80–87. https://doi.org/10.1016/0022-510X(92)90191-MCrossRefPubMed

30.

Hartai Z, Klivenyi P, Janaky T, Penke B, Vecsei L (2005) Kynurenine metabolism in multiple sclerosis. Acta Neurol Scand 112(2):93–96. https://doi.org/10.1111/j.1600-0404.2005.00442.xCrossRefPubMed

31.

Rejdak K, Bartosik-Psujek H, Dobosz B, Kocki T, Grieb P, Giovannoni G., Turski W.A., Stelmasiak Z. (2002) Decreased level of kynurenic acid in cerebrospinal fluid of relapsing-onset multiple sclerosis patients. Neurosci Lett 331(1):0–65. https://doi.org/10.1016/s0304-3940(02)00710-3, 63

32.

Rejdak K, Petzold A, Kocki T, Kurzepa J, Grieb P, Turski WA, Stelmasiak Z (2007) Astrocytic activation in relation to inflammatory markers during clinical exacerbation of relapsing-remitting multiple sclerosis. J Neural Transm 114(8):1011–1015. https://doi.org/10.1007/s00702-007-0667-yCrossRefPubMed

33.

Havelund JF, Andersen AD, Binzer M, Blaabjerg M, Heegaard NHH, Stenager E, Faergeman NJ, Gramsbergen JB (2017) Changes in kynurenine pathway metabolism in Parkinson patients with L-DOPA-induced dyskinesia. J Neurochem 142:745–766. https://doi.org/10.1111/jnc.14104CrossRef

34.

Cheng ML, Chang KH, Wu YR, Chen CM (2016) Metabolic disturbances in plasma as biomarkers for Huntington disease. J NutrBiochem 31:38–44. https://doi.org/10.1016/j.jnutbio.2015.12.001CrossRef

35.

Lewitt PA, Li J, Lu M, Beach TG, Adler CH et al (2013) 3-hydroxykynurenine and other Parkinson’s disease biomarkers discovered by metabolomic analysis. Mov Disord 28(12):1653–1660. https://doi.org/10.1002/mds.25555CrossRefPubMed

Title: Urinary kynurenine as a biomarker for Parkinson’s disease
Authors: Jia-he Bai
Ya-li Zheng
Yong-peng Yu
Publication date: 01-02-2021
Publisher: Springer International Publishing
Keywords: Parkinson's Disease
Mild Cognitive Impairment
Biomarkers
Published in: Neurological Sciences / Issue 2/2021
Print ISSN: 1590-1874
Electronic ISSN: 1590-3478
DOI: https://doi.org/10.1007/s10072-020-04589-x

At a glance: The STEP trials

Springer Medicine

Urinary kynurenine as a biomarker for Parkinson’s disease

Abstract

Objective

Method

Results

Conclusion

At a glance: The STEP trials

Springer Medicine

Abstract

Objective

Method

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 2/2021

Association between serum paraoxonase 1 activity and its polymorphisms with multiple sclerosis: a systematic review

Evaluation of serum uric levels in migraine

DAPT score: predictive model of dual-antiplatelet therapy for acute cerebral infarction

Medulloblastoma of the adult: results from a multicenter retrospective study by AINO (Italian Association of Neuro-Oncology) and SIN (Italian Society of Neurology)

Coffin-Siris syndrome and epilepsy

Multimodal evaluation of the cerebrovascular reserve in Neurofibromatosis type 1 patients with Moyamoya syndrome